Outcomes Focused Innovation Driven March 2023

2 Presentation disclaimer This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements are based on management’s current beliefs and expectations. These statements include but are not limited to statements regarding Inhibrx, Inc.’s (the “Company”) business strategy, the Company’s plans to develop and commercialize its product candidates, the safety and efficacy of the Company’s product candidates, the Company’s plans and expected timing with respect to clinical trials and regulatory filings and approvals, manufacturing matters, strength of intellectual property protection, and the size and growth potential of the markets for the Company’s product candidates, and any implication that pre-clinical data or preliminary or topline results will be representative of the results of later trials. This presentation also contains certain projections and estimates regarding the Company’s future financial performance, namely potential future revenue for certain of the Company’s product candidates. This information also constitutes forward-looking information and is for illustrative purposes only and should not be relied upon as necessarily being indicative of any future results. The assumptions and estimates underlying this estimated financial information are inherently uncertain and subject to a wide variety of significant business, economic competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. These potential financial information and other forward-looking statements involve substantial known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Additional information regarding the Company’s risks and uncertainties are described from time to time in the “Risk Factors” section of our Securities and Exchange Commission filings, including those described in our Annual Report on Form 10-K as well as our Quarterly Reports on Form 10-Q, and supplemented from time to time by our Current Reports on Form 8-K. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company’s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes. The forward-looking statements in this presentation represent the Company’s views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company has no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this presentation. The investigational product candidates discussed in this presentation have not been approved or licensed by the U.S. Food and Drug Administration or by any other regulatory authority, and they are not commercially available in any market. This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of the Company’s future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk. Inhibrx, the Inhibrx logo and ContraMAB are registered trademarks of Inhibrx, Inc. All third-party trademarks used herein are registered trademarks of their respective owners. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities.

3 Why Inhibrx Should Be Front and Center on Your Radar Four Biologic Programs in the Clinic All are demonstrating clinical activity with multi-billion-dollar potential peak sales. Two potentially registration-enabling programs are underway in 1H 2023. Our Interests are Aligned With Our Investors Credible base of major holders and ~30% internally owned. Potential to become financially self- sustaining within 18 months with no debt and possible return of capital to investors through share buy-backs and/or special dividends. Opportunities to Both Partner Assets and Commercialize In-house We believe our assets appeal to major pharmaceutical companies as licensing targets. We are building the infrastructure to internally execute on small commercial footprint opportunities. Active Discovery Process Six programs are expected to enter the clinic over the next three years.

4 Innovative Approach to Biologic Therapeutic Discovery & Development Broad Internal Expertise + The modular nature of our platforms and technologies combined with our protein engineering expertise allow for rapid exploration of therapeutic approaches + Teams with deep biologics drug development expertise across translational sciences, clinical, technical operations, manufacturing and commercial + Best targets are known and already explored, but what is not known is how to drug them properly + We learn through prior clinical failures and therapeutic liabilities + We only move programs into the clinic that are first or best-in-class with a clear path to point of concept Settlers, Not Pioneers Success Where Others Have Failed + First company to optimize and develop recombinant AAT + First company to overcome DR5 agonism toxicity challenges and advance into registration-enabling study + First company to find a therapeutic window for 4-1BB

5 + No innovation for 30+ years and multiple recombinant AAT failures + Favorable safety and tolerability profile w/potential to achieve normal AAT levels with monthly dosing + Site activation and enrollment initiation for potentially registration-enabling trial expected in April 2023; Potential path to launch in 2026; $3B+ peak sales potential + Prior DR5 agonist efforts failed due to limited activity or hepatotoxicity + At-risk population for severe liver toxicity now identified and currently updated screening criteria protocol + Data from potentially registration-enabling trial expected in 2H 2024 with possible path to approval in chondrosarcoma in 2025; $1B peak sales potential and exploring expansion into other indications INBRX-109 Our Tetravalent DR5 Agonist + OX40 is a validated target but no one has been able to build a viable multivalent antibody + Clinical data looks promising with durable single agent activity + Substantial data update in 1H 2024 with registration studies as early as 2H 2024 INBRX-106 Our Hexavalent OX40 Agonist INBRX-105 Our Tetravalent PD-L1 targeted 4-1BB Agonist + We believe we are the first to find a therapeutic window for 4-1BB agonism + Based on incoming clinical data, we are growing more confident this could be a blockbuster drug, potentially as a single agent + Data update in 2H 2023 with potential for registration studies to start early next year INBRX-101- AATD Our Recombinant Alpha-1-Anti-trypsin Fc-Fusion Protein (AAT-Fc) Potentially registration- Preclinical Phase 1 enabling Our Therapeutic Candidates